

## RMC-6236, pan-RAS inhibitor

Catalog	Unit
TBI3976-1MG	1 mg
TBI3976-5MG	5 mg

### Product Details

**Formal Name:** (1S,2S)-N-[(7S,13S)-21-ethyl-20-[2-[(1S)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)pyridin-3-yl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tetrazapentacyclo[17.5.2.12.5.19,13.022,26]octacosal(25),2,5(28),19,22(26),23-hexaen-7-yl]-2-methylcyclopropane-1-carboxamide

**Alternate Name:** Daraxonrasib

**Molecular Formula:** C<sub>44</sub>H<sub>58</sub>N<sub>8</sub>O<sub>5</sub>S

**Formula Weight:** 811.1

**CAS Number:** 2765081-21-6


**Purity:** >98%

**Formulation:** Powder

**Solubility:** Soluble in DMSO (> 75 mg/ml)

**Storage:** -20°C

**Stability:** ≥ 2 years



### Applications

pan-RAS inhibitor

### Functions

Broad spectrum inhibitor of both mutant and wild-type KRAS, NRAS, and HRAS variants. It binds with high affinity to cyclophilin A ( $K_D = 55$  nM) creating a binary complex that has high affinity for the active state of KRAS ( $K_D = 131$  nM for G12V, 364 nM for G12D and 154 nM for wild type). Active in in vivo xenograft models of NSCLC, PDAC, colorectal cancer, gastric carcinoma, and ovarian adenocarcinoma.

### Application Procedures

First dissolved in DMSO (> 75 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 1 month.

**For research use only.**